The DOI matches its Crossref record; 202 of the 202 references it cites were found in a registry or an index.
Cellular Responses to Cisplatin‐Induced DNA Damage
Open accessAbstract
Cisplatin is one of the most effective anticancer agents widely used in the treatment of solid tumors. It is generally considered as a cytotoxic drug which kills cancer cells by damaging DNA and inhibiting DNA synthesis. How cells respond to cisplatin‐induced DNA damage plays a critical role in deciding cisplatin sensitivity. Cisplatin‐induced DNA damage activates various signaling pathways to prevent or promote cell death. This paper summarizes our current understandings regarding the mechanisms by which cisplatin induces cell death and the bases of cisplatin resistance. We have discussed various steps, including the entry of cisplatin inside cells, DNA repair, drug detoxification, DNA damage response, and regulation of cisplatin‐induced apoptosis by protein kinases. An understanding of how various signaling pathways regulate cisplatin‐induced cell death should aid in the development of more effective therapeutic strategies for the treatment of cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
3 retracted
Akt Phosphorylation and Stabilization of X-linked Inhibitor of Apoptosis Protein (XIAP)
Dan, H. C., Sun, M., Kaneko, S., Feldman, R. I., Nicosia, S. V., Wang, H.-G., Tsang, B. K., & Cheng, J. Q. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m312044200 · Cited by 422
RetractedAKT2 Inhibition of Cisplatin-induced JNK/p38 and Bax Activation by Phosphorylation of ASK1
Yuan, Z.-Q., Feldman, R. I., Sussman, G. E., Coppola, D., Nicosia, S. V., & Cheng, J. Q. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m302674200 · Cited by 203
RetractedKim, H. S., Hwang, J. T., Yun, H., Chi, S., Lee, S., Kang, I., Yoon, K., Choe, W.-J., Kim, S. S., & Ha, J. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m704432200 · Cited by 83
RetractedMammalian MAP kinase signalling cascades
Chang, L., & Karin, M. (2001) · Nature · doi:10.1038/35065000 · Cited by 5,111
The resurgence of platinum-based cancer chemotherapy
Kelland, L. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2167 · Cited by 4,717
Intracellular Signaling by Hydrolysis of Phospholipids and Activation of Protein Kinase C
Nishizuka, Y. (1992) · Science · doi:10.1126/science.1411571 · Cited by 4,472
Mitogen-Activated Protein Kinase Pathways Mediated by ERK, JNK, and p38 Protein Kinases
Johnson, G. L., & Lapadat, R. (2002) · Science · doi:10.1126/science.1072682 · Cited by 4,295
Platinum Compounds: a New Class of Potent Antitumour Agents
ROSENBERG, B., VANCAMP, L., TROSKO, J. E., & MANSOUR, V. H. (1969) · Nature · doi:10.1038/222385a0 · Cited by 3,972
Marshall, C. J. (1995) · Cell · doi:10.1016/0092-8674(95)90401-8 · Cited by 3,906
Cellular processing of platinum anticancer drugs
Wang, D., & Lippard, S. J. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1691 · Cited by 3,801
Inhibition of Cell Division in Escherichia coli by Electrolysis Products from a Platinum Electrode
ROSENBERG, B., VAN CAMP, L., & KRIGAS, T. (1965) · Nature · doi:10.1038/205698a0 · Cited by 3,049
Structure, Recognition, and Processing of Cisplatin−DNA Adducts
Jamieson, E. R., & Lippard, S. J. (1999) · Chemical Reviews · doi:10.1021/cr980421n · Cited by 2,949
Kischkel, F. C., Hellbardt, S., Behrmann, I., Germer, M., Pawlita, M., Krammer, P. H., & Peter, M. E. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb00245.x · Cited by 2,184
Apoptosis. Its significance in cancer and cancer Therapy
Kerr, J. F. R., Winterford, C. M., & Harmon, B. V. (1994) · Cancer · doi:10.1002/1097-0142(19940415)73:8<2013::aid-cncr2820730802>3.0.co;2-j · Cited by 2,132
Ten years of protein kinase B signalling: a hard Akt to follow
Brazil, D. P., & Hemmings, B. A. (2001) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(01)01958-2 · Cited by 1,177
Yang, H., Kong, W., He, L., Zhao, J.-J., O'Donnell, J. D., Wang, J., Wenham, R. M., Coppola, D., Kruk, P. A., Nicosia, S. V., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2488 · Cited by 1,051
Caspases: the proteases of the apoptotic pathway
Nuñez, G., Benedict, M. A., Hu, Y., & Inohara, N. (1998) · Oncogene · doi:10.1038/sj.onc.1202581 · Cited by 1,046
The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage
Gong, J., Costanzo, A., Yang, H.-Q., Melino, G., Kaelin, W. G., Levrero, M., & Wang, J. Y. J. (1999) · Nature · doi:10.1038/21690 · Cited by 930
Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals
Ishida, S., Lee, J., Thiele, D. J., & Herskowitz, I. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162491399 · Cited by 927
Godwin, A. K., Meister, A., O'Dwyer, P. J., Huang, C. S., Hamilton, T. C., & Anderson, M. E. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.7.3070 · Cited by 925
Mechanisms of resistance to cisplatin
Kartalou, M., & Essigmann, J. M. (2001) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/s0027-5107(01)00141-5 · Cited by 869
Regulation of the ABC kinases by phosphorylation: protein kinase C as a paradigm
NEWTON, A. C. (2003) · Biochemical Journal · doi:10.1042/bj20021626 · Cited by 798
Requirement for ERK Activation in Cisplatin-induced Apoptosis
Wang, X., Martindale, J. L., & Holbrook, N. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m004583200 · Cited by 675
Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair.
Chu, G. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)42175-2 · Cited by 651
Biochemical Mechanisms of Cisplatin Cytotoxicity
Cepeda, V., Fuertes, M. A., Castilla, J., Alonso, C., Quevedo, C., & Perez, J. M. (2007) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152007779314044 · Cited by 649
Overexpression of Metallothionein Confers Resistance to Anticancer Drugs
Kelley, S. L., Basu, A., Teicher, B. A., Hacker, M. P., Hamer, D. H., & Lazo, J. S. (1988) · Science · doi:10.1126/science.3175622 · Cited by 601
Self-citationCellular accumulation of the anticancer agent cisplatin: A review
Gately, D., & Howell, S. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.221 · Cited by 572
Eastman, A. (1987) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(87)90009-x · Cited by 539
Inhibition of transcription by platinum antitumor compounds
Todd, R. C., & Lippard, S. J. (2009) · Metallomics · doi:10.1039/b907567d · Cited by 539
Cisplatin and DNA repair in cancer chemotherapy
Zamble, D. B., & Lippard, S. J. (1995) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(00)89095-7 · Cited by 538
Ishikawa, T., & Ali-Osman, F. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(20)80702-9 · Cited by 533
Charles F. Kettring prize. Fundamental studies with cisplatin
Rosenberg, B. (1985) · Cancer · doi:10.1002/1097-0142(19850515)55:10<2303::aid-cncr2820551002>3.0.co;2-l · Cited by 517
Loss of DNA mismatch repair in acquired resistance to cisplatin.
Aebi, S. P., Kurdi-Haidar, B., Gordon, R. T., Cenni, B., Zheng, H., Fink, D. A., Christen, R. D., Boland, C. R., Koi, M., Fishel, R. A., et al. (1996) · PubMed · Cited by 502
Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline.
Fan, S., Smith, M. L., Rivet, D. J., Duba, D. E., Zhan, Q., Kohn, K. W., Fornace, A. J., & O'Connor, P. M. (1995) · PubMed · Cited by 490
Activation of the c-Abl tyrosine kinase in the stress response to DMA-damaging agents
Kharbanda, S., Ren, R., Pandey, P., Shafman, T. D., Feller, S. M., Weichselbaum, R. R., & Kufe, D. W. (1995) · Nature · doi:10.1038/376785a0 · Cited by 485
The Role of Cellular Accumulation in Determining Sensitivity to Platinum-Based Chemotherapy
Hall, M. D., Okabe, M., Shen, D.-W., Liang, X.-J., & Gottesman, M. M. (2008) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.080907.180426 · Cited by 474
Ghayur, T., Hugunin, M., Talanian, R. V., Ratnofsky, S., Quinlan, C., Emoto, Y., Pandey, P., Datta, R., Huang, Y., Kharbanda, S., et al. (1996) · The Journal of Experimental Medicine · doi:10.1084/jem.184.6.2399 · Cited by 472
Fujiwara, T., Grimm, E. A., Mukhopadhyay, T., Zhang, W. W., Owen‐Schaub, L. B., & Roth, J. A. (1994) · PubMed · Cited by 464
Zanke, B. W., Boudreau, K., Rubie, E., Winnett, E., Tibbles, L. A., Zon, L., Kyriakis, J., Liu, F.-F., & Woodgett, J. R. (1996) · Current Biology · doi:10.1016/s0960-9822(02)00547-x · Cited by 444
p53: Guardian of the Genome and Policeman of the Oncogenes
Efeyan, A., & Serrano, M. (2007) · Cell Cycle · doi:10.4161/cc.6.9.4211 · Cited by 439
Metallothioneins in human tumors and potential roles in carcinogenesis
Cherian, M. G., Jayasurya, A., & Bay, B.-H. (2003) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2003.07.013 · Cited by 437
Houghton, A. N., & Polsky, D. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00161-7 · Cited by 414
Activation of programmed cell death by anticancer agents: cisplatin as a model system.
Eastman, A. R. (1990) · PubMed · Cited by 398
Roles of the metallothionein family of proteins in the central nervous system
Hidalgo, J., Aschner, M., Zatta, P., & Vašák, M. (2001) · Brain Research Bulletin · doi:10.1016/s0361-9230(01)00452-x · Cited by 387
Perego, P., Giarola, M., Righetti, S. C., Supino, R., Caserini, C., Delia, D., Pierotti, M. A., Miyashita, T., Reed, J. C., & Zunino, F. (1996) · PubMed · Cited by 384
Mansouri, A., Ridgway, L. D., Korapati, A. L., Zhang, Q., Tian, L., Wang, Y., Siddik, Z. H., Mills, G. B., & Claret, F. X. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m208134200 · Cited by 377
Recognition of cisplatin adducts by cellular proteins
Kartalou, M., & Essigmann, J. M. (2001) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/s0027-5107(01)00142-7 · Cited by 349
Levy, D., Adamovich, Y., Reuven, N., & Shaul, Y. (2008) · Molecular Cell · doi:10.1016/j.molcel.2007.12.022 · Cited by 347
Inhibition of the c-Abl–TAp63 pathway protects mouse oocytes from chemotherapy-induced death
Gonfloni, S., Di Tella, L., Caldarola, S., Cannata, S. M., Klinger, F. G., Di Bartolomeo, C., Mattei, M., Candi, E., De Felici, M., Melino, G., et al. (2009) · Nature Medicine · doi:10.1038/nm.2033 · Cited by 346
Copper Transporters and the Cellular Pharmacology of the Platinum-Containing Cancer Drugs
Howell, S. B., Safaei, R., Larson, C. A., & Sailor, M. J. (2010) · Molecular Pharmacology · doi:10.1124/mol.109.063172 · Cited by 344
Asselin, É., Mills, G. B., & Tsang, B. K. (2001) · PubMed · Cited by 335
Holzer, A. K., Manorek, G. H., & Howell, S. B. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.022624 · Cited by 322
TLR4 Signaling Mediates Inflammation and Tissue Injury in Nephrotoxicity
Zhang, B., Ramesh, G., Uematsu, S., Akira, S., & Reeves, W. B. (2008) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007090982 · Cited by 317
ATR-Chk2 Signaling in p53 Activation and DNA Damage Response during Cisplatin-induced Apoptosis
Pabla, N., Huang, S., Mi, Q.-S., Daniel, R., & Dong, Z. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m707568200 · Cited by 309
Köberle, B., Masters, J. R. W., Hartley, J. A., & Wood, R. D. (1999) · Current Biology · doi:10.1016/s0960-9822(99)80118-3 · Cited by 300
Effect of Extracellular Signal-regulated Kinase on p53 Accumulation in Response to Cisplatin
Persons, D. L., Yazlovitskaya, E. M., & Pelling, J. C. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m004267200 · Cited by 290
Righetti, S. C., Torre, G. D., Pilotti, S., Ménard, S., Ottone, F., Colnaghi, M. I., Pierotti, M. A., Lavarino, C. E., Cornarotti, M., Oriana, S., et al. (1996) · PubMed · Cited by 276
Weir, N. M., Selvendiran, K., Kutala, V. K., Tong, L., Vishwanath, S., Rajaram, M., Tridandapani, S., Anant, S., & Kuppusamy, P. (2007) · Cancer Biology & Therapy · doi:10.4161/cbt.6.2.3577 · Cited by 275
Leong, C.-O., Vidnovic, N., DeYoung, M. P., Sgroi, D., & Ellisen, L. W. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30866 · Cited by 270
p38 MAP kinase inhibition ameliorates cisplatin nephrotoxicity in mice
Ramesh, G., & Reeves, W. B. (2005) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00401.2004 · Cited by 267
Nowak, G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m206373200 · Cited by 265
Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs
Safaei, R., & Howell, S. B. (2005) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2004.09.007 · Cited by 254
Kang, T.-H., Lindsey-Boltz, L. A., Reardon, J. T., & Sancar, A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0915085107 · Cited by 250
Yang, X., Fraser, M., Moll, U. M., Basak, A., & Tsang, B. K. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-0425 · Cited by 248
Hayakawa, J., Ohmichi, M., Kurachi, H., Kanda, Y., Hisamoto, K., Nishio, Y., Adachi, K., Tasaka, K., Kanzaki, T., & Murata, Y. (2000) · PubMed · Cited by 243
Brown, R., Hirst, G. L., Gallagher, W. M., McIlwrath, A. J., Margison, G. P., van der Zee, A. G., & Anthoney, D. A. (1997) · Oncogene · doi:10.1038/sj.onc.1201167 · Cited by 243
Persons, D. L., Yazlovitskaya, E. M., Cui, W., & Pelling, J. C. (1999) · PubMed · Cited by 237
Cisplatin induces a persistent activation of JNK that is related to cell death
Sánchez-Perez, I., Murguía, J. R., & Perona, R. (1998) · Oncogene · doi:10.1038/sj.onc.1201578 · Cited by 236
Jo, S.-K., Cho, W. Y., Sung, S. A., Kim, H. K., & Won, N. H. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.67102.x · Cited by 235
Potapova, O., Haghighi, A., Bost, F., Liu, C., Birrer, M. J., Gjerset, R., & Mercola, D. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.22.14041 · Cited by 229
Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines
Welsh, C., Day, R., McGurk, C., Masters, J. R. W., Wood, R. D., & Köberle, B. (2004) · International Journal of Cancer · doi:10.1002/ijc.20134 · Cited by 215
Regulation of PUMA-α by p53 in cisplatin-induced renal cell apoptosis
Jiang, M., Wei, Q., Wang, J., Du, Q., Yu, J., Zhang, L., & Dong, Z. (2006) · Oncogene · doi:10.1038/sj.onc.1209440 · Cited by 209
Bypass of DNA Lesions Generated During Anticancer Treatment with Cisplatin by DNA Polymerase η
Alt, A., Lammens, K., Chiocchini, C., Lammens, A., Pieck, J. C., Kuch, D., Hopfner, K.-P., & Carell, T. (2007) · Science · doi:10.1126/science.1148242 · Cited by 203
Increased accumulation of p53 protein in cisplatin‐resistant ovarian cell lines
Brown, R., Clugston, C., Edlin, A., Vasey, P., Kaye, S. B., Burns, P., & Vojtěšek, B. (1993) · International Journal of Cancer · doi:10.1002/ijc.2910550428 · Cited by 202
The potential of protein kinase C as A target for anticancer treatment
Basu, A. (1993) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(93)90070-t · Cited by 197
Self-citationSedletska, Y., Giraud-Panis, M.-J., & Malinge, J.-M. (2005) · Current Medicinal Chemistry-Anti-Cancer Agents · doi:10.2174/1568011053765967 · Cited by 195
An Msh2 Point Mutation Uncouples DNA Mismatch Repair and Apoptosis
Lin, D. P., Wang, Y., Scherer, S. J., Clark, A. B., Yang, K., Avdievich, E., Jin, B., Werling, U., Parris, T., Kurihara, N., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2957 · Cited by 195
Cisplatin induces PKB/Akt activation and p38MAPK phosphorylation of the EGF receptor
Winograd-Katz, S. E., & Levitzki, A. (2006) · Oncogene · doi:10.1038/sj.onc.1209737 · Cited by 195
How do real tumors become resistant to cisplatin?
Borst, P., Rottenberg, S., & Jonkers, J. (2008) · Cell Cycle · doi:10.4161/cc.7.10.5930 · Cited by 192
Liu, L.-Z., Zhou, X.-D., Qian, G., Shi, X., Fang, J., & Jiang, B.-H. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4261 · Cited by 189
Fraser, M. E., Leung, B. M., Yan, X., Dan, H. C., Cheng, J. Q., & Tsang, B. K. (2003) · PubMed · Cited by 187
Ban, N., Takahashi, Y., Takayama, T., Kura, T., Katahira, T., Sakamaki, S., & Niitsu, Y. (1996) · PubMed · Cited by 183
Downregulation of XPF–ERCC1 enhances cisplatin efficacy in cancer cells☆
Arora, S., Kothandapani, A., Tillison, K., Kalman-Maltese, V., & Patrick, S. M. (2010) · DNA Repair · doi:10.1016/j.dnarep.2010.03.010 · Cited by 182
Metallothionein expression in human neoplasia
Theocharis, S. E., Margeli, A. P., Klijanienko, J. T., & Kouraklis, G. P. (2004) · Histopathology · doi:10.1111/j.1365-2559.2004.01922.x · Cited by 179
Metallothionein-mediated cisplatin resistance in human ovarian carcinoma cells
Andrews, P., Murphy, M., & Howell, S. (1987) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00254568 · Cited by 176
Hayakawa, J., Ohmichi, M., Kurachi, H., Ikegami, H., Kimura, A., Matsuoka, T., Jikihara, H., Mercola, D., & Murata, Y. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.44.31648 · Cited by 175
Involvement of protein kinase C-δ in DNA damage-induced apoptosis
Basu, A., Woolard, M. D., & Johnson, C. L. (2001) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4400885 · Cited by 173
Self-citationMechanism of transcriptional stalling at cisplatin-damaged DNA
Damsma, G. E., Alt, A., Brueckner, F., Carell, T., & Cramer, P. (2007) · Nature Structural & Molecular Biology · doi:10.1038/nsmb1314 · Cited by 171
Shimodaira, H., Yoshioka-Yamashita, A., Kolodner, R. D., & Wang, J. Y. J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0438031100 · Cited by 168
Role of ERK activation in cisplatin‐induced apoptosis in OK renal epithelial cells
Kim, Y. K., Kim, H. J., Kwon, C. H., Kim, J. H., Woo, J. S., Jung, J. S., & Kim, J. M. (2005) · Journal of Applied Toxicology · doi:10.1002/jat.1081 · Cited by 167
Role of the p38 MAPK pathway in cisplatin-based therapy
Losa, J. H., Cobo, C. P., Viniegra, J. G., Lobo, V. J. S.-A., Cajal, S. R. Y., & Sánchez-Prieto, R. (2003) · Oncogene · doi:10.1038/sj.onc.1206608 · Cited by 166
Dominant effects of an Msh6 missense mutation on DNA repair and cancer susceptibility
Yang, G., Scherer, S. J., Shell, S. S., Yang, K., Kim, M., Lipkin, M., Kucherlapati, R., Kolodner, R. D., & Edelmann, W. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.024 · Cited by 166
Selective recognition of a cisplatin-DNA adduct by human mismatch repair proteins
Yamada, M. (1997) · Nucleic Acids Research · doi:10.1093/nar/25.3.491 · Cited by 161
Drummond, J. T., Genschel, J., Wolf, E., & Modrich, P. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.19.10144 · Cited by 158
Nucleotide Excision Repair Pathways Involved in Cisplatin Resistance in Non-Small-Cell Lung Cancer
Rosell, R., Tarón, M., Barnadas, A., et al. (2003) · Cancer Control · doi:10.1177/107327480301000404 · Cited by 156
Blair, B. G., Larson, C., Safaei, R., & Howell, S. B. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0311 · Cited by 154
Kasherman, Y., Stürup, S., & Gibson, D. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900138u · Cited by 152
p53-dependent and -independent responses to cisplatin in mouse testicular teratocarcinoma cells
Zamble, D. B., Jacks, T., & Lippard, S. J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6163 · Cited by 149
Holzer, A. K., Katano, K., Klomp, L. W. J., & Howell, S. B. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0748 · Cited by 143
MicroRNA-34a Is Induced via p53 during Cisplatin Nephrotoxicity and Contributes to Cell Survival
Bhatt, K. S., Zhou, L., Mi, Q., Huang, S., She, J., & Dong, Z. (2010) · Molecular Medicine · doi:10.2119/molmed.2010.00002 · Cited by 140
Protein kinase Cε makes the life and death decision
Basu, A., & Sivaprasad, U. (2007) · Cellular Signalling · doi:10.1016/j.cellsig.2007.04.008 · Cited by 137
Self-citationYeh, P.-Y., Chuang, S., Yeh, K., Song, Y., Ea, C.-K., & Cheng, A. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)00908-5 · Cited by 136
Abedini, M. R., Muller, É., Bergeron, R., Gray, D. A., & Tsang, B. K. (2009) · Oncogene · doi:10.1038/onc.2009.300 · Cited by 130
Evolution of Functions within the p53/p63/p73 Family
Laurenzi, V. D., & Melino, G. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb05602.x · Cited by 130
Nehmé, A., Baskaran, R., Aebi, S. P., Fink, D. A., Nebel, S., Cenni, B., Wang, J. Y. J., Howell, S. B., & Christen, R. D. (1997) · PubMed · Cited by 129
Nanoparticle-mediated targeting of MAPK signaling predisposes tumor to chemotherapy
Basu, S., Harfouche, R., Soni, S., Chimote, G., Mashelkar, R. A., & Sengupta, S. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0902857106 · Cited by 129
Dependence of the Cytotoxicity of DNA-Damaging Agents on the Mismatch Repair Status of Human Cells
Papouli, E., Ćejka, P., & Jiricny, J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0513 · Cited by 128
Gagnon, V., Themsche, C. V., Turner, S., Leblanc, V., & Asselin, É. (2007) · APOPTOSIS · doi:10.1007/s10495-007-0165-6 · Cited by 128
Branch, P., Masson, M., Aquilina, G., Bignami, M., & Karran, P. (2000) · Oncogene · doi:10.1038/sj.onc.1203668 · Cited by 126
Overcoming Glutathione S -Transferase P1–Related Cisplatin Resistance in Osteosarcoma
Pasello, M., Michelacci, F., Scionti, I., Hattinger, C. M., Zuntini, M., Caccuri, A. M., Scotlandi, K., Picci, P., & Serra, M. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5840 · Cited by 125
Zhang, L., Huang, J., Yang, N., Liang, S., Barchetti, A., Giannakakis, A., Cadungog, M. G., O’Brien-Jenkins, A., Massobrio, M., Roby, K. F., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4527 · Cited by 123
Hofmann, J., Doppler, W., Jakob, A., Maly, K., Posch, L., Überall, F., & Grunicke, H. H. (1988) · International Journal of Cancer · doi:10.1002/ijc.2910420313 · Cited by 120
Yeh, P.-Y., Yeh, K., Chuang, S., Song, Y., & Cheng, A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m402362200 · Cited by 119
Involvement of protein kinase C‐δ in DNA damage‐induced apoptosis
Basu, A. (2003) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2003.tb00237.x · Cited by 118
Self-citationOrelli, B., McClendon, T. B., Tsodikov, O. V., Ellenberger, T., Niedernhofer, L. J., & Schärer, O. D. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.067538 · Cited by 116
Tang, M. K. S., Zhou, H., Yam, J. W. P., & Wong, A. S. T. (2010) · Neoplasia · doi:10.1593/neo.91438 · Cited by 115
The role of copper transporters in the development of resistance to Pt drugs
Safaei, R., Holzer, A. K., Katano, K., Samimi, G., & Howell, S. B. (2004) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2004.05.006 · Cited by 114
AKT involvement in cisplatin chemoresistance of human uterine cancer cells
Gagnon, V., Mathieu, I., Sexton, É., Leblanc, K., & Asselin, É. (2004) · Gynecologic Oncology · doi:10.1016/j.ygyno.2004.06.023 · Cited by 112
Nehmé, A., Baskaran, R., Nebel, S., Fink, D. A., Howell, S. B., Wang, J. Y. J., & Christen, R. D. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690176 · Cited by 111
Lin, X., Ramamurthi, K., Mishima, M., Kondo, A., Christen, R. D., & Howell, S. B. (2001) · PubMed · Cited by 106
Cisplatin Damage: Are DNA Repair Proteins Saviors or Traitors to the Cell?
Zorbas, H., & Keppler, B. K. (2005) · ChemBioChem · doi:10.1002/cbic.200400427 · Cited by 103
Zhuo, W., Wang, Y., Zhuo, X., Zhang, Y., Xu-jun, A., & Chen, Z. (2008) · Lung Cancer · doi:10.1016/j.lungcan.2008.02.007 · Cited by 103
Belyanskaya, L. L., Hopkins-Donaldson, S., Kurtz, S., Simões‐Wüst, A. P., Yousefi, S., Simon, H., Stahel, R. A., & Zangemeister‐Wittke, U. (2005) · International Journal of Cancer · doi:10.1002/ijc.21242 · Cited by 101
A new p38 MAP kinase‐regulated transcriptional coactivator that stimulates p53‐dependent apoptosis
Cuadrado, A., Lafarga, V., Cheung, P., Dolado, I., Llanos, S., Cohen, P., & Nebreda, Á. R. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601657 · Cited by 101
Woessmann, W., Chen, X., & Borkhardt, A. (2002) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-002-0502-y · Cited by 101
Zhuo, W., Wang, Y., Zhuo, X.-L., Zhang, Y., & Chen, Z. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.02.143 · Cited by 99
Yan, X., Fraser, M. E., Qiu, Q., & Tsang, B. K. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2005.12.033 · Cited by 99
Role of glutathione S -transferase P1-1 in the cellular detoxification of cisplatin
Peklak-Scott, C., Smitherman, P. K., Townsend, A. J., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0250 · Cited by 98
McKay, B. C., Becerril, C., & Ljungman, M. E. (2001) · Oncogene · doi:10.1038/sj.onc.1204901 · Cited by 98
Yang, C., Kaushal, V., Haun, R. S., Seth, R., Shah, S. V., & Kaushal, G. P. (2007) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4402287 · Cited by 97
Schweyer, S., Soruri, A., Meschter, O., Heintze, A., Zschunke, F., Miosge, N., Thelen, P., Schlott, T., Radzun, H., & Fayyazi, A. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601919 · Cited by 97
Piaggi, S., Raggi, C., Corti, A., Pitzalis, E., Mascherpa, M. C., Saviozzi, M., Alfonso Pompella, C., & Casini, A. (2010) · Carcinogenesis · doi:10.1093/carcin/bgq031 · Cited by 96
Regulation of p73-mediated apoptosis by c-Jun N-terminal kinase
Jones, E. V., Dickman, M. J., & Whitmarsh, A. J. (2007) · Biochemical Journal · doi:10.1042/bj20061778 · Cited by 95
Ohta, T., Ohmichi, M., Hayasaka, T., Mabuchi, S., Saitoh, M., Kawagoe, J., Takahashi, K., Igarashi, H., Du, B., Doshida, M., et al. (2006) · Endocrinology · doi:10.1210/en.2005-1450 · Cited by 94
Cisplatin Cytotoxicity: DNA and Plasma Membrane Targets
Rébillard, A., Lagadic‐Gossmann, D., & Dimanche‐Boitrel, M. (2008) · Current Medicinal Chemistry · doi:10.2174/092986708786242903 · Cited by 94
c-Abl stabilizes p73 by a phosphorylation-augmented interaction.
Tsai, K. K., & Yuan, Z.-M. (2003) · PubMed · Cited by 93
Basu, A., Teicher, B. A., & Lazo, J. S. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)38909-4 · Cited by 92
Self-citationActivation of MEK Kinase 1 by the c-Abl Protein Tyrosine Kinase in Response to DNA Damage
Kharbanda, S. M., Pandey, P., Yamauchi, T., Kumar, S., Kaneki, M., Kumar, V., Bharti, A. K., Yuan, Z.-M., Ghanem, L. R., Rana, A., et al. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.14.4979-4989.2000 · Cited by 92
Effect of JNK inhibition on cisplatin-induced renal damage
Francescato, H. D. C., Costa, R. S., Junior, F. B., & Coimbra, T. M. (2007) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfm144 · Cited by 91
Activation of Phosphatidylinositol-3′-kinase/AKT Signaling Is Essential in Hepatoblastoma Survival
Hartmann, W., Küchler, J. N., Koch, A., Friedrichs, N., Waha, A., Endl, E., Czerwitzki, J., Metzger, D., Steiner, S., Wurst, P., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2878 · Cited by 90
Lin, X., & Howell, S. B. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0491 · Cited by 89
Claerhout, S., Verschooten, L., Kelst, S. V., Vos, R. D., Proby, C. M., Agostinis, P., & Garmyn, M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25300 · Cited by 88
Kondo, S., Barna, B. P., Kondo, Y., Tanaka, Y., Casey, G., Liu, J., Morimura, T., Kaakaji, R., Peterson, J. W., Werbel, B., et al. (1996) · PubMed · Cited by 88
Isonishi, S., Andrews, P. A., & Howell, S. B. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)39638-3 · Cited by 86
Kawai, K., Kamatani, N., Georges, E., & Ling, V. W. T. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)38277-8 · Cited by 85
Cisplatin Induces p53-Dependent FLICE-Like Inhibitory Protein Ubiquitination in Ovarian Cancer Cells
Abedini, M. R., Muller, É., Brun, J., Bergeron, R., Gray, D. A., & Tsang, B. K. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0673 · Cited by 83
Mismatch Repair Protein Deficiency Compromises Cisplatin-induced Apoptotic Signaling
Topping, R. P., Wilkinson, J. C., & Scarpinato, K. D. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m809303200 · Cited by 82
Molecular Determinants of the Cytotoxicity of Platinum Compounds
Vekris, A., Meynard, D., Haaz, M., Bayssas, M., Bonnet, J., & Robert, J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2258 · Cited by 82
Role of ERCC1 promoter hypermethylation in drug resistance to cisplatin in human gliomas
Chen, H., Shao, C., Chen, F., Kwan, A., & Chen, Z. (2009) · International Journal of Cancer · doi:10.1002/ijc.24772 · Cited by 81
Surowiak, P., Materna, V., Maciejczyk, A., Pudełko, M., Markwitz, E., Spaczyński, M., Dietel, M., Zabel, M., & Lage, H. (2007) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-006-0362-7 · Cited by 81
Basu, A., & Akkaraju, G. R. (1999) · Biochemistry · doi:10.1021/bi982854q · Cited by 80
Self-citationChen, H., Song, I., Hossain, A., Choi, M., YAMANE, Y., Zheng, L., Lu, J., Wu, L. Y. H., Siddik, Z. H., Klomp, L. W. J., et al. (2008) · Molecular Pharmacology · doi:10.1124/mol.108.047969 · Cited by 80
c-Jun Regulates the Stability and Activity of the p53 Homologue, p73
Toh, W. H., Siddique, M. M., Boominathan, L., Lin, K. W., & Sabapathy, K. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m407672200 · Cited by 77
Sensitization of human cervical carcinoma cells to cis-diamminedichloroplatinum(II) by bryostatin 1.
Basu, A., & Lazo, J. S. (1992) · PubMed · Cited by 73
Self-citationActivation of ERK during DNA damage-induced apoptosis involves protein kinase Cδ
Basu, A., & Tu, H. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.06.199 · Cited by 70
Self-citationThe MEK1 inhibitor PD98059 sensitizes C8161 melanoma cells to cisplatin-induced apoptosis
Mandic, A., Viktorsson, K., Heiden, T., Hansson, J., & Shoshan, M. C. (2001) · Melanoma Research · doi:10.1097/00008390-200102000-00002 · Cited by 67
Truong, T., Sun, G., Doorly, M., Wang, J. Y. J., & Schwartz, M. A. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1635435100 · Cited by 67
Colton, S. L., Xu, X. S., Wang, Y. A., & Wang, G. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m602826200 · Cited by 65
Zhang, Y., & Shen, X. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2090 · Cited by 64
Baldwin, R. M., Garratt-Lalonde, M., Parolin, D. A. E., Krzyzanowski, P. M., Andrade-Navarro, M. A., & Lorimer, I. A. J. (2005) · Oncogene · doi:10.1038/sj.onc.1209312 · Cited by 63
LaPensee, E. W., Schwemberger, S. J., LaPensee, C. R., Bahassi, E. M., Afton, S. E., & Ben‐Jonathan, N. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp120 · Cited by 63
Miyazaki, M., Kohno, K., Saburi, Y., et al. (1990) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(90)91016-l · Cited by 62
Wu, X., Fan, W., Xu, S., & Zhou, Y. (2003) · PubMed · Cited by 62
p53 gene status and chemosensitivity in ovarian cancer.
Kigawa, J., Sato, S., Shimada, M., Takahashi, M., Itamochi, H., Kanamori, Y., & Terakawa, N. (2001) · PubMed · Cited by 61
Regulation of p53 target gene expression by cisplatin-induced extracellular signal-regulated kinase
DeHaan, R. D., Yazlovitskaya, E. M., & Persons, D. L. (2001) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800100318 · Cited by 61
Geiger, T. M., Müller, M., Dean, N. M., & Fabbro, D. (1998) · PubMed · Cited by 58
Fourrier, L., Brooks, P., & Malinge, J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301390200 · Cited by 57
Park, S. A., Park, H. J., Lee, B. I., Ahn, Y., Kim, S. U., & Choi, K. S. (2001) · Molecular Brain Research · doi:10.1016/s0169-328x(01)00176-0 · Cited by 56
Akt1 inhibition by RNA interference sensitizes human non‐small cell lung cancer cells to cisplatin
Lee, M. W., Kim, D. S., Min, N. Y., & Kim, H. T. (2008) · International Journal of Cancer · doi:10.1002/ijc.23371 · Cited by 55
Requirement of caspase-mediated cleavage of c-Abl during stress-induced apoptosis
Machuy, N., Rajalingam, K., & Rudel, T. (2003) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401336 · Cited by 49
Kütük, Ö., Arısan, E. D., Tezil, T., Shoshan, M. C., & Başağa, H. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp165 · Cited by 46
Distinct effects of the recurrent Mlh1 G67R mutation on MMR functions, cancer, and meiosis
Avdievich, E., Reiß, C., Scherer, S. J., Zhang, Y., Maier, S. M., Jin, B., Hou, H., Rosenwald, A., Riedmiller, H. N., Kucherlapati, R., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0800276105 · Cited by 44
Lee, S., Yoon, S., & Kim, D. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2006.08.040 · Cited by 41
Down-regulation of Caspase-2 by Rottlerin via Protein Kinase C-δ–Independent Pathway
Basu, A., Adkins, B., & Basu, C. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6244 · Cited by 40
Self-citationMohanty, S., Huang, J., & Basu, A. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0450 · Cited by 40
Self-citationGalán‐Moya, E. M., Hernández‐Losa, J., Luquero, C. I. A., de la Cruz-Morcillo, M. Á., Ramírez‐Castillejo, C., Callejas‐Valera, J. L., Arriaga, A., Fernández, A., y Cajal, S. R., Gutkind, J. S., et al. (2007) · International Journal of Cancer · doi:10.1002/ijc.23063 · Cited by 38
Nicotine, through upregulating pro‐survival signaling, cooperates with NNK to promote transformation
Nishioka, T., Guo, J., Yamamoto, D., Chen, L., Hüppi, P. S., & Chen, C. Y. (2009) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22392 · Cited by 37
Nezhat, F. R., Wadler, S., Muggia, F. M., Mandeli, J., Goldberg, G. L., Rahaman, J., Runowicz, C. D., Murgo, A. J., & Gardner, G. J. (2004) · Gynecologic Oncology · doi:10.1016/j.ygyno.2003.12.021 · Cited by 36
Preyer, M., Shu, C.-W., & Wang, J. Y. J. (2007) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4402119 · Cited by 35
p53 binds to cisplatin-damaged DNA
Wetzel, C. C., & Berberich, S. J. (2001) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(00)00305-5 · Cited by 34
Guthrie, O. W., Li‐Korotky, H., Durrant, J. D., & Balaban, C. D. (2008) · Hearing Research · doi:10.1016/j.heares.2008.01.013 · Cited by 34
Basu, A., Kozikowski, A. P., Sato, K., & Lazo, J. S. (1991) · PubMed · Cited by 34
Self-citationCytokeratin 8 silencing in human nasopharyngeal carcinoma cells leads to cisplatin sensitization
Wang, Y., He, Q., Tsao, S., Cheung, Y. H., Wong, A., & Chiu, J. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.02.015 · Cited by 31
Phospholipase A2-activating protein (PLAA) enhances cisplatin-induced apoptosis in HeLa cells
Zhang, F., Suárez, G., Sha, J., Sierra, J. C., Peterson, J. W., & Chopra, A. K. (2009) · Cellular Signalling · doi:10.1016/j.cellsig.2009.02.018 · Cited by 31
Bhana, S., & Lloyd, D. R. (2007) · Mutagenesis · doi:10.1093/mutage/gem041 · Cited by 31
Regulation of p53 stabilization by DNA damage and protein kinase C.
Johnson, C., Lu, D., Huang, J., & Basu, A. (2002) · PubMed · Cited by 31
Self-citationConstitutive activation of p70 S6 kinase is associated with intrinsic resistance to cisplatin
Dhar, R., & Basu, A. (2008) · International Journal of Oncology · doi:10.3892/ijo.32.5.1133 · Cited by 30
Self-citationMLH1 expression sensitises ovarian cancer cells to cell death mediated by XIAP inhibition
Ding, X.-Y., Mohd, A. B., Huang, Z., Baba, T., Bernardini, M. Q., Lyerly, H. K., Berchuck, A., Murphy, S. K., Buermeyer, A. B., & Devi, G. R. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605180 · Cited by 29
Persaud, S. D., Hoang, V., Huang, J., & Basu, A. (2005) · International Journal of Oncology · doi:10.3892/ijo.27.1.149 · Cited by 28
Self-citationKanamori, Y., Kigawa, J., Minagawa, Y., Irie, T., Oishi, T., Shimada, M., Takahashi, M., Nakamura, T., Sato, K., & Terakawa, N. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00199-3 · Cited by 28
Basu, A., & Weixel, K. M. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910620416 · Cited by 27
Self-citationBoubakari, Bracht, K., Neumann, C., et al. (2004) · Archiv der Pharmazie · doi:10.1002/ardp.200400620 · Cited by 27
Sedletska, Y., Fourrier, L., & Malinge, J. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.02.048 · Cited by 24
Kigawa, J., Sato, S., Shimada, M., Kanamori, Y., Itamochi, H., & Terakawa, N. (2002) · Gynecologic Oncology · doi:10.1006/gyno.2001.6488 · Cited by 22
Hirata, J., Kikuchi, Y., Kita, T., et al. (1993) · International Journal of Cancer · doi:10.1002/ijc.2910550332 · Cited by 16
Zhang, X., Sanmun, D., Hu, L., Fadeel, B., & Ernberg, I. T. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.06.043 · Cited by 15
Lomonaco, S. L., Xu, X., & Wang, G. (2009) · DNA and Cell Biology · doi:10.1089/dna.2008.0815 · Cited by 13
Cisplatin-induced nitrosylation of p53 prevents its mitochondrial translocation
Hernlund, E., Kütük, Ö., Başağa, H., Linder, S. T., Panaretakis, T., & Shoshan, M. C. (2009) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2009.03.015 · Cited by 13
Iioka, Y., Mishima, K., Azuma, N., Tsuchida, A., Takagi, Y., Aoki, T., & Saito, I. (2005) · Pathobiology · doi:10.1159/000084119 · Cited by 13
Molecular alterations of cells resistant to platinum drugs: Role of PKCα
Righetti, S. C., Perego, P., Carenini, N., Corna, E., Bo, L. D., Cedrola, S., Porta, C. A. M. L., & Zunino, F. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2005.12.007 · Cited by 13
Cited by
Cisplatin in cancer therapy: Molecular mechanisms of action
Dasari, S., & Bernard Tchounwou, P. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.07.025 · Cited by 5,537
Cisplatin: The first metal based anticancer drug
Ghosh, S. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.102925 · Cited by 1,751
Suraweera, A., O’Byrne, K. J., & Richard, D. J. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00092 · Cited by 669
Cisplatin nephrotoxicity: new insights and therapeutic implications
Tang, C., Livingston, M. J., Safirstein, R., & Dong, Z. (2023) · Nature Reviews Nephrology · doi:10.1038/s41581-022-00631-7 · Cited by 548
Volarevic, V., Djokovic, B., Jankovic, M. G., Harrell, C. R., Fellabaum, C., Djonov, V., & Arsenijevic, N. (2019) · Journal of Biomedical Science · doi:10.1186/s12929-019-0518-9 · Cited by 438
Metadata
- Authors
- Basu, A., & Krishnamurthy, S.
- Venue
- Journal of Nucleic Acids
- Publisher
- Wiley
- Published
- 2010-01
- Volume
- 2010
- Issue
- 1
- ISSN
- 2090-0201 (ISSN-L)
- 2090-021X
- OpenAlex
- W2037288471
- Cited by
- 569
- References
- 202
- FWCI
- 7.98
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.